In an 84-year-old woman with Alzheimer disease, chronic atrial fibrillation on apixaban, currently taking sertraline 100 mg daily and bupropion extended‑release 150 mg daily, who has markedly worsened depression, insomnia, and poor appetite after her husband’s death, what is the optimal pharmacologic and non‑pharmacologic management?

Optimize Current Antidepressant Regimen and Prioritize Non-Pharmacologic Interventions

Given the worsening depression despite dual antidepressant therapy, you should first increase sertraline to 150-200 mg daily (the current 100 mg is subtherapeutic for treatment-resistant depression) while continuing bupropion XL 150 mg, and simultaneously implement structured non-pharmacologic interventions including caregiver education, environmental modifications, and bereavement support. 1

Immediate Medication Optimization

The patient is on sertraline 100 mg and bupropion XL 150 mg—both are at mid-range doses with room for titration. Sertraline and bupropion combination therapy has demonstrated efficacy in treatment-refractory depression 2, and this patient's worsening symptoms 6 months post-bereavement suggest inadequate dosing rather than medication failure.

Specific Dosing Strategy:

• Increase sertraline to 150 mg daily immediately, with plan to advance to 200 mg daily in 2 weeks if no response 1
• Maintain bupropion XL at 150 mg (avoid increasing to 300 mg in elderly patients with dementia due to seizure risk, particularly given her age and Alzheimer's) 3
• Sertraline is specifically recommended as first-line for depression in Alzheimer's disease due to minimal anticholinergic effects 1

The evidence strongly supports SSRIs in Alzheimer's-related depression: sertraline showed 38% full response and 46% partial response rates versus 20% and 15% with placebo in the DIADS trial 4. A 2023 meta-analysis confirmed SSRIs significantly alleviate depressive symptoms in AD patients (SMD 0.905, p<0.000), with sertraline specifically effective (SMD 0.818, p<0.000) 5.

Critical caveat: One large trial (HTA-SADD) found no benefit of sertraline over placebo at 13 weeks 6, but this study has been criticized for inadequate dosing and the current patient's combination therapy may overcome monotherapy limitations 2.

Non-Pharmacologic Interventions Are First-Line

Non-pharmacologic approaches must be implemented immediately—they are recommended as preferred first-line treatment for neuropsychiatric symptoms in dementia by multiple expert panels 7. The guidelines explicitly state these should be exhausted before adding psychotropics 1.

Specific Interventions to Implement:

For Depression and Bereavement:

• Structured bereavement counseling (her husband died 6 months ago—this is complicated grief requiring specific intervention)
• Caregiver education on the "three R's" approach: repeat, reassure, redirect 1
• Day program enrollment for social engagement and structured activities 1

For Insomnia (address this separately from depression):

• Establish rigid sleep hygiene: fixed bedtime/wake time, limit daytime napping to <30 minutes before 3 PM 8
• Environmental modifications: reduce nighttime lighting, eliminate TV/noise, use nightlights to prevent confusion 1
• Consider low-dose trazodone 25-50 mg at bedtime if non-pharmacologic measures fail after 2 weeks 9

For Poor Appetite:

• Scheduled, predictable mealtimes with familiar foods 1
• Social eating (meals with others improve intake)
• Rule out medication-induced nausea from sertraline (though she's been on it chronically) 10

Monitoring and Reassessment Timeline

Assess response within 1-2 weeks of sertraline increase, then again at 6-8 weeks 11. The ACP guidelines are explicit: modify treatment if inadequate response by 6-8 weeks 11.

What to Monitor:

• Suicidality: SSRIs increase risk of suicide attempts (OR 1.57-2.25 vs placebo), particularly in first 1-2 months 11, 10. Weekly contact initially.
• Serotonin syndrome risk: She's on bupropion + sertraline—watch for agitation, confusion, tremor, autonomic instability 10
• Bleeding risk: Apixaban + sertraline increases bleeding risk through serotonin effects on platelets 10
• Hyponatremia: Common with SSRIs in elderly; check sodium at 2 weeks and 8 weeks 11

If Inadequate Response at 8 Weeks

Switch strategies rather than adding a third agent. The evidence for augmentation in elderly dementia patients is extremely limited 7.

Preferred Second-Line Options:

1. Switch to mirtazapine 7.5-30 mg at bedtime 1—addresses depression, insomnia, and poor appetite simultaneously; well-tolerated in elderly 12
2. Switch to venlafaxine or vortioxetine (safer drug interaction profiles than fluoxetine) 12
3. Avoid tricyclics entirely (anticholinergic burden worsens cognition in Alzheimer's) 12

Critical Safety Considerations

Apixaban continuation is appropriate—she has atrial fibrillation with a pacemaker, and DOACs are preferred over warfarin in elderly AF patients, including those with dementia 13, 14, 15. Apixaban specifically shows favorable bleeding profiles in frail elderly 13, 14.

Bupropion seizure risk: At 150 mg daily, seizure risk is acceptable, but do not increase dose. Bupropion is contraindicated if seizure history exists 3. Her Alzheimer's disease increases baseline seizure risk.

Drug interactions to avoid: Do not add MAOIs, linezolid, or methylene blue (serotonin syndrome risk with sertraline) 10. Avoid adding antipsychotics unless psychosis emerges (increased mortality in dementia) 7.

Environmental Safety Measures

Given her dementia and depression with passive death wishes:

• Remove firearms, medications, sharp objects from easy access
• Install safety locks on doors/gates (wandering risk) 1
• Register in Alzheimer's Association Safe Return Program 1
• Ensure 24-hour supervision or monitoring system

11, 7, 11, 1, 11, 12, 10, 3, 6, 5, 4, 2, 13, 14, 15